Sutro Biopharma
STRO
Sutro Biopharma (STRO) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wedbush | Maintained | Outperform | $60.00 | Aug 13, 2026 |
| Citizens | Maintained | Market Outperform | $34.00 from $41.00 | Aug 13, 2026 |
| Truist Securities | Initiated Coverage | Buy | $50.00 | Jun 11, 2026 |
| Barclays | Initiated Coverage | Overweight | $56.00 | May 28, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $50.00 from $28.00 | May 15, 2026 |
| Wedbush | Upgraded | Neutral → Outperform | $60.00 from $22.00 | May 15, 2026 |
| Leerink Partners | Maintained | Outperform | $43.00 from $38.00 | May 15, 2026 |
| Mizuho | Initiated Coverage | Outperform | $50.00 | Apr 30, 2026 |
| Citizens | Maintained | Market Outperform | $41.00 from $35.00 | Apr 23, 2026 |
| Citizens | Maintained | Market Outperform | $35.00 from $23.00 | Apr 17, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $38.00 | Apr 7, 2026 |
| Deutsche Bank | Maintained | Buy | $55.00 from $51.00 | Mar 25, 2026 |
| HC Wainwright & Co. | Upgraded | Neutral → Buy | $28.00 from $10.00 | Mar 24, 2026 |
| Wells Fargo | Upgraded | Equal-Weight → Overweight | $27.00 from $8.00 | Mar 24, 2026 |
| Citizens | Upgraded | Market Perform → Market Outperform | $23.00 | Jan 20, 2026 |
| HC Wainwright & Co. | Maintained | Neutral | $10.00 from $2.00 | Dec 22, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $3.00 from $4.00 | Aug 12, 2025 |
| Piper Sandler | Upgraded | Neutral → Overweight | $2.00 | Jun 16, 2025 |
| B of A Securities | Maintained | Underperform | $0.80 from $1.00 | May 19, 2025 |
| HC Wainwright & Co. | Maintained | Neutral | $2.00 | Apr 29, 2025 |
Frequently asked questions
What is the latest analyst rating on STRO?
On Aug 13, 2026, Wedbush maintained Sutro Biopharma at Outperform with a price target of $60.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.